Cutaneous T-Cell Lymphoma Outcomes During COVID-19
September 2021
in “
Journal of the American Academy of Dermatology
”
TLDR CTCL patients can safely continue treatment during COVID-19 with proper safety measures.
The study conducted at New York-Presbyterian Hospital and Columbia University Irving Medical Center reviewed the outcomes of 6 patients with cutaneous T-cell lymphoma (CTCL) who also had confirmed or suspected COVID-19. Diagnoses included mycosis fungoides, Sézary syndrome, and primary cutaneous CD30+ lymphoproliferative disorder. Treatments involved oral medications, infusions, and phototherapy. Due to safety concerns, 3 patients with stable CTCL experienced treatment interruptions, leading to disease relapse in 2 of them. The study highlights that with effective safety measures, continued care for CTCL patients can be provided safely, minimizing interruptions in necessary therapies.